Scopolamine
Scopolamine (hyoscine) — Devil's Breath, burundanga — is a naturally-occurring deliriant of the tropane alkaloid class. It is the more potent relative of atropine, producing stronger sedation and amnesia. It blocks acetylcholine signaling throughout the brain and body, causing sedation, memory loss, and at high doses, full delirium.[1]
Scopolamine (hyoscine) — Devil's Breath, burundanga — is a naturally-occurring deliriant of the tropane alkaloid class. It is the more centrally potent relative of atropine, with stronger sedative and amnestic properties. Scopolamine is a non-selective muscarinic acetylcholine receptor antagonist, producing its effects by blocking acetylcholine signaling throughout the brain and peripheral nervous system.[1]
Albert Ladenburg isolated scopolamine in 1880, and it entered clinical medicine around 1900 as a presurgical sedative. Its amnesia and suggestibility effects led to use as a "truth serum" in the 1920s and, more recently, to criminal exploitation as a chemical incapacitating agent.[2] It is now a prescription medicine for motion sickness and surgical nausea, listed on the WHO Essential Medicines list.[3]
Subjective effects include dry mouth, sedation, visual acuity suppression, memory loss, disorientation, and at higher doses, vivid realistic hallucinations. The experience is defined by subtraction — attention, memory, and reality-testing erode progressively until invented perceptions are indistinguishable from the real world. Rapid heart rate, inability to sweat, urinary retention, and total loss of behavioral control are characteristic unwanted effects.
Scopolamine produces little dependence at clinical doses, but the gap between therapeutic and toxic exposure is narrow.[4] The main danger is impaired sweating — heat causes rapid overheating, and combining it with other anticholinergic drugs sharply amplifies delirium risk.[5] Clinical pharmacology is well established from decades of medical use, though antidepressant evidence remains actively contested.[6]
History[edit]
Discovery
Albert Ladenburg first isolated scopolamine from Scopolia carniolica in 1880.[7] The alternative name hyoscine, used in British pharmacopoeias, comes from Hyoscyamus niger (black henbane). Full chemical synthesis was not achieved until 1959.[7]
Clinical and cultural significance
Scopolamine entered clinical medicine around 1900 in twilight sleep — a morphine–scopolamine combination for childbirth that produced semiconsciousness with subsequent amnesia.[8] It was abandoned after reports of neonatal breathing problems and maternal delirium. In the 1920s it became briefly popular as a "truth serum" before being replaced by barbiturate-based approaches.[7]
Modern era
In 1979, Transderm Scōp became the first commercially available transdermal drug delivery system in pharmaceutical history.[9] In 2006, NIMH researchers discovered rapid antidepressant effects from intravenous scopolamine, sparking significant interest but remaining contested.[10][6] Subsequent research identified sex-dependent response patterns.[11][12]
The name scopolamine honors Antonio Scopoli (1723–1788), the Italian naturalist who described the genus Scopolia. The nightshade plants that produce it — belladonna, henbane, mandrake, jimsonweed — carry deep roots in European folklore as poisons and ritual substances associated with witchcraft.[3] In 1910, Dr. Hawley Harvey Crippen was convicted of murdering his wife with scopolamine — one of the earliest forensic identifications of the compound in a homicide.[7]
Chemistry[edit]
Structural class
Scopolamine belongs to the substituted tropane chemical class, sharing its core scaffold with atropine and cocaine.[7] The defining structural feature is a 6,7-epoxide bridge across the tropane ring, which increases brain penetration and gives scopolamine greater central sedative potency than atropine. Its molecular formula is C₁₇H₂₁NO₄, with a molecular weight of 303.35 g/mol.[13]
Stereochemistry
Natural scopolamine is the levo-enantiomer — only this form is active at muscarinic receptors; the mirror-image form is inactive.[1] The hydrobromide trihydrate salt is the standard pharmaceutical form, chosen for its stability and water solubility.[14] Commercial pharmaceutical scopolamine is extracted from cultivated Duboisia hybrids in Australia rather than synthesized.[3]
Pharmacology[edit]
Mechanism of action
Scopolamine blocks muscarinic acetylcholine receptors throughout the brain and body.[15][1] This drives dry mouth, dilated pupils, tachycardia, reduced gut movement, and urinary retention in the body — and sedation, amnesia, and nausea suppression in the brain.[4] Blocking a feedback receptor also releases the brakes on dopamine-producing neurons, raising dopamine and other signaling molecules in the frontal cortex.[16][17]
Antidepressant mechanism (emerging)
Scopolamine's antidepressant effects last for weeks after a single infusion, long after the drug has left the bloodstream.[18] This suggests the drug triggers lasting changes in brain wiring rather than simply occupying receptors — a mechanism that converges on the same plasticity pathways as ketamine.[19][15]
Pharmacokinetics
By mouth, scopolamine is poorly and variably absorbed.[1][20] The transdermal patch delivers a steady dose over 72 hours, reaching peak blood levels around 8 hours after application.[9] Scopolamine crosses into the brain readily and also crosses the placenta; it is present in breast milk.[1]
Neuroscience[edit]
Where it acts
Scopolamine blocks acetylcholine receptors in the hippocampus and prefrontal cortex, producing cognitive impairment and amnesia. Blocking a feedback receptor on the same neurons briefly triggers a burst of acetylcholine release before the dominant suppressive effect takes hold.[16] This also releases the brakes on dopamine-producing neurons, raising dopamine, serotonin, and glutamate in the frontal cortex.[17]
Why it matters
Depression may involve excess acetylcholine activity relative to norepinephrine. Genetic variants in the main acetylcholine receptor gene are linked to depression susceptibility,[21] supporting this model. Blocking that excess may be the basis for scopolamine's rapid mood-lifting effects.[22]
This places scopolamine alongside ketamine and psilocybin in an emerging group of compounds that promote rapid brain rewiring through shared downstream pathways.[15][19]
Does scopolamine produce genuine antidepressant effects, or do its peripheral side effects break the blind and inflate apparent efficacy? The active-placebo trial[6] raised this challenge but may have been underpowered. Women show both larger antidepressant responses[12] and different blood-level kinetics,[23] suggesting unexplained sex-dependent mechanisms.
Subjective Effects[edit]
Scopolamine's experience is defined by subtraction. It does not enrich perception — it progressively erases attention, memory formation, and reality-testing. At clinical doses this is a mild cognitive fog. As dose increases, the world fills with phantom objects, absent people, and invented conversations that feel entirely real and are forgotten completely.
Compared to diphenhydramine, scopolamine produces a more sedating, amnestic profile with less restless dysphoria. Compared to whole-plant Datura preparations, purified scopolamine is pharmacologically cleaner but equally dangerous — without the unpredictable atropine and hyoscyamine contributions that make plant-based exposures particularly erratic.
First isolated from Scopolia carniolica by Albert Ladenburg in 1880, scopolamine entered clinical medicine as a pre-anesthetic sedative and obstetric analgesic before finding its modern role in motion sickness and postoperative nausea prevention. Its combination of amnesia and suggestibility led to early use as a "truth serum" and, in modern times, to criminal exploitation as a chemical incapacitating agent.[2] It appears on the WHO Model List of Essential Medicines[3] and is unscheduled in all major jurisdictions.
Subjective effects include sedation, anterograde amnesia, dry mouth, pupil dilation, and at supratherapeutic doses, delirium with vivid external hallucinations. The experience is one of cognitive erasure — a progressive dissolution of attention, memory formation, and reality testing that culminates in a waking state where fabricated perceptions are indistinguishable from the real environment. Tachycardia, urinary retention, impaired thermoregulation, and profound disorientation are characteristic unsought effects.
Scopolamine produces negligible dependence at clinical doses, but the margin between therapeutic and toxic exposure is narrow — delirium has been reported from standard transdermal patches in children and elderly patients.[4] Anticholinergic toxidrome compounds impaired thermoregulation with cardiovascular stress and complete loss of behavioral control; chronic exposure is associated with increased dementia risk.[5] Clinical pharmacology is well-characterized from decades of medical use, though the antidepressant evidence base remains actively contested[6] and the complete metabolic profile is still incomplete.
History[edit]
Discovery
Albert Ladenburg first isolated scopolamine from Scopolia carniolica in 1880, building on his earlier tropane alkaloid work that had included the synthesis of atropine in 1875.[7] The alternative name hyoscine, used in British pharmacopoeias, derives from Hyoscyamus niger (black henbane), another Solanaceae source. Full chemical synthesis was not achieved until 1959.[7]
Clinical and cultural significance
Scopolamine entered clinical medicine around 1900, most notably in twilight sleep (Dämmerschlaf) — a morphine–scopolamine combination for obstetric analgesia that produced semiconsciousness with subsequent amnesia, championed by feminist advocates as a right to pain-free childbirth but abandoned following reports of neonatal respiratory depression and maternal delirium.[8] In the 1920s it was briefly adopted as a "truth serum" in American courts, based on the observation that subjects exhibited enhanced suggestibility, before being superseded by barbiturate-based approaches.[7] Military requirements during World War II — preventing seasickness during amphibious landings — drove systematic antiemetic research that established scopolamine's modern clinical identity.[9]
Modern era
In 1979, Transderm Scōp became the first commercially available transdermal drug delivery system in pharmaceutical history, pioneering an entirely new route of drug administration.[10] The most significant recent development came in 2006, when NIMH researchers serendipitously discovered rapid antidepressant effects from intravenous scopolamine in a pilot trial originally designed to study cholinergic modulation of cognition.[11] Subsequent replication identified sex-dependent response patterns,[12][13] though a later active-placebo-controlled trial found no separation from a peripherally active comparator.[6]
The name scopolamine honors Antonio Scopoli (1723–1788), the Italian naturalist who described the genus Scopolia. The Solanaceae plants that produce the compound — belladonna, henbane, mandrake, jimsonweed — occupy deep roots in European folklore as poisons, sedatives, and ritual substances associated with witchcraft traditions.[3] In 1910, Dr. Hawley Harvey Crippen was convicted of murdering his wife with scopolamine — one of the earliest forensic identifications of the compound in a homicide case.[7]
Chemistry[edit]
Structural class
Scopolamine belongs to the substituted tropane chemical class, sharing the tropane scaffold with atropine and cocaine. The defining structural feature is a 6,7-epoxide bridge across the tropane ring, forming a tricyclic system that distinguishes it from atropine.[7] This epoxide increases molecular polarity, enhances blood–brain barrier penetration, and confers greater central sedative potency relative to atropine.
The tropic acid ester at C-7 constitutes the pharmacophore for muscarinic acetylcholine receptor binding. Hydrolysis of this ester bond by plasma or hepatic enzymes abolishes antimuscarinic activity.
Molecular identity
| Molecular formula | C₁₇H₂₁NO₄ |
| Molecular weight | 303.35 g/mol |
The molecule consists of a rigid tricyclic ring system esterified with (S)-tropic acid. Balanced lipophilic–hydrophilic character enables efficient blood–brain barrier penetration while maintaining adequate water solubility for injectable formulations. The hydrobromide trihydrate salt is the most commonly used pharmaceutical form, offering improved stability over the free base.[15]
Stereochemistry
Scopolamine contains four stereocenters — three in the tropane ring and one in the tropic acid side chain. Natural scopolamine is the levo-enantiomer ((−)-scopolamine).[15] Only the L-form possesses significant pharmacological activity at muscarinic receptors; the dextrorotatory enantiomer is inactive and absent from natural sources or pharmaceutical preparations.[1]
Natural occurrence
Commercial pharmaceutical scopolamine is extracted from cultivated Duboisia hybrids in Australia rather than produced by total synthesis, reflecting the economic advantage of plant-based production for this structurally complex molecule.[3]
Pharmacology[edit]
Mechanism of action
Scopolamine competitively blocks muscarinic acetylcholine receptors across all five subtypes (M1–M5) with roughly equal affinity.[16][1] This broad muscarinic antagonism drives both peripheral effects — dry mouth, dilated pupils, rapid heart rate, reduced gut motility — and central effects including sedation, amnesia, and nausea suppression.[4] A minor affinity at histamine H₁ receptors has also been reported.[4]
In the brain, M1 receptor blockade in the hippocampus and prefrontal cortex produces cognitive impairment and amnesia. M2 autoreceptor blockade in subcortical regions disinhibits dopamine-releasing neurons, increasing dopamine output. Action on muscarinic receptors in the vestibular nuclei and the brain's vomiting center produces the antiemetic effect.[17]
Peripheral effects follow from muscarinic blockade in target organs: dilated pupils and loss of near-focus (iris and ciliary muscle), dry mouth (salivary glands), rapid heart rate (heart's pacemaker node), reduced sweating (sweat glands), slowed digestion (gut smooth muscle), urinary retention (bladder muscle), and airway relaxation (bronchial muscle).[4][1]
Antidepressant mechanism (emerging)
Beyond direct muscarinic blockade, scopolamine's putative antidepressant effects involve downstream changes in glutamate signaling and synaptic remodeling. The compound's short plasma half-life (~4.5 hours) contrasts with antidepressant effects persisting for weeks after a single infusion, suggesting lasting changes in gene expression and synapse formation rather than sustained receptor occupancy.[18]
Proposed downstream mechanisms include activation of the mTORC1 plasticity pathway in prefrontal cortex,[16] dephosphorylation of eEF2 — a mechanism shared with ketamine's rapid antidepressant action[19] — elevation of dopamine, serotonin, and glutamate in frontal regions,[20] and modulation of BDNF signaling.[16] The cholinergic–adrenergic hypothesis posits that depression reflects excess central cholinergic tone relative to noradrenergic tone, providing the rationale for muscarinic antagonism as an antidepressant strategy.[21]
Pharmacokinetics
Scopolamine's pharmacokinetics vary dramatically by route. Following intravenous administration, the mean elimination half-life is approximately 4.5 hours.[22] Oral bioavailability is highly variable (10.7–48.2%) due to extensive first-pass liver metabolism — less than 2.6% of unchanged drug is recovered in urine after oral dosing.[1][22] Peak plasma levels occur approximately 30 minutes after oral administration.[1]
The transdermal patch (Transderm Scōp) delivers a priming dose from the adhesive layer followed by steady-state release at approximately 5 µg/hour over 72 hours, with peak plasma concentrations reached around 8 hours after application.[10]
Metabolism proceeds primarily through glucuronide conjugation and oxidative pathways. The complete metabolic profile remains incompletely characterized.[1] Scopolamine crosses the blood–brain barrier readily, crosses the placenta, and is present in breast milk.[1]
Neuroscience[edit]
Where it acts
Scopolamine's central effects arise from muscarinic acetylcholine receptor blockade across several brain structures. M1 receptors on hippocampal and prefrontal neurons mediate the cognitive and amnestic effects, while M2 autoreceptors on cholinergic projection neurons regulate acetylcholine release in a negative feedback loop — blocking them paradoxically triggers a brief burst of acetylcholine release before the dominant inhibitory effects take hold.[17]
M2 blockade in subcortical structures also disinhibits dopaminergic neurons, increasing dopamine, serotonin, and glutamate in the frontal cortex.[20] This neurochemical cascade may explain both the transient mood-lifting effects observed in antidepressant trials and the frank delirium that emerges at higher doses.
Why it matters
The cholinergic–adrenergic balance hypothesis frames depression as an excess of central cholinergic tone relative to noradrenergic tone, positioning muscarinic antagonism as a rebalancing strategy.[21] Genetic support comes from CHRM2 polymorphisms linked to depression susceptibility.[23]
Scopolamine's rapid antidepressant effects place it alongside ketamine and psilocybin in an emerging class of compounds that promote rapid synaptic remodeling. Despite distinct primary targets — muscarinic antagonism, NMDA antagonism, and 5-HT₂A agonism respectively — all three converge on mTORC1 and BDNF signaling pathways that drive new synapse formation in prefrontal cortex.[16][19]
Does scopolamine produce genuine central antidepressant effects, or do peripheral side effects break the blind and inflate apparent efficacy? The active-placebo trial[6] raised this challenge but may have been underpowered to resolve it. Women show both larger antidepressant responses[13] and different plasma kinetics,[24] suggesting sex-dependent mechanisms that remain unexplained.
Subjective Effects[edit]
Scopolamine's experiential character is defined by subtraction rather than addition — a progressive erosion of cognitive function rather than the perceptual enrichment of serotonergic psychedelics or the anesthetic detachment of dissociatives. At low clinical doses, the experience centers on drying of the mouth and eyes, mild sedation, and an attentional fog. As dose increases, memory formation fails first, followed by orientation and reality testing, until a full delirium emerges in which realistic hallucinations — phantom conversations, shadow figures, mundane objects that are not present — are accepted without question and forgotten completely afterward. Context is a critical modifier: in involuntary exposure, suggestibility and amnesia become the dominant functional effects.
Compared to diphenhydramine at equivalent anticholinergic loads, scopolamine produces a more sedating, amnestic profile with less of the restless dysphoria that characterizes antihistamine-driven delirium. Compared to whole-plant Datura preparations, purified scopolamine delivers a pharmacologically cleaner but equally dangerous exposure, without the variable atropine and hyoscyamine contributions that make plant-derived anticholinergic experiences particularly unpredictable.
Effect Grid
The full therapeutic antimuscarinic profile is established. Significant dry mouth is the most prominent physical effect, accompanied by blurred vision from cycloplegia and pupil dilation. Sedation is moderate and consistent. Measurable anterograde amnesia develops — new information is poorly encoded, and recall of events during this period will be incomplete.
Heart rate increases noticeably (tachycardia from M2 blockade). Gastrointestinal motility is reduced, producing constipation. Body temperature regulation is mildly compromised as sweat gland output decreases. EEG changes are detectable — increased theta/delta activity with decreased alpha power.
This tier corresponds to standard clinical dosing: 0.3–0.6 mg oral or one transdermal patch (0.5 mg delivered over 72 hours). Cognitive impairment is significant — driving and operating machinery are unsafe. Nausea suppression, the primary therapeutic effect, is fully active.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Vestibular distortion · Auditory misinterpretation · Light sensitivity · Visual haze / noise · Auditory distortion · Depth perception distortion · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Visual morphing · Dreaming suppression · External hallucinations · Visual processing suppression · Auditory hallucinations · Object activation · Object transformations · Shadow people · Internal hallucinations · Perspective hallucinations · Olfactory hallucination
Auditory distortion · Depth perception distortion · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Visual morphing · Dreaming suppression · External hallucinations · Visual processing suppression · Auditory hallucinations · Object activation · Object transformations · Shadow people · Internal hallucinations · Perspective hallucinations · Olfactory hallucination
Constipation · Dehydration sensation · Dizziness · Heart rate perception changes · Temperature dysregulation · Headache · Physical fatigue · Restlessness · Sedation · Body schema distortion · Breathing alteration · Stimulation · Insomnia · Nausea · Nystagmus (eye wobbles) · Trembling · Vomiting · Wakefulness · Bodily dissociation · Tactile hallucination
Heart rate perception changes · Headache · Physical fatigue · Restlessness · Sedation · Body schema distortion · Breathing alteration · Stimulation · Insomnia · Nausea · Nystagmus (eye wobbles) · Trembling · Vomiting · Wakefulness · Bodily dissociation · Tactile hallucination
Information processing suppression · Memory suppression · Analysis suppression · Thought disorganization · Cognitive dysphoria · Cognitive fatigue · Memory fragmentation · Pattern recognition suppression · Delusions of sobriety · Language suppression · Motivation suppression · Thought deceleration · Thought loops · Amnesia · Delirium · Delusions
Thought disorganization · Cognitive dysphoria · Cognitive fatigue · Memory fragmentation · Pattern recognition suppression · Language suppression · Motivation suppression · Thought deceleration · Thought loops · Amnesia · Delirium · Delusions
Anxiety suppression · Emotional lability · Mania · Euphoria
Social disconnection · Trust enhancement · Automaticity · Depersonalization · Derealization · Sociability suppression · Cognitive disconnection · Identity alteration
Derealization · Sociability suppression · Cognitive disconnection · Identity alteration
Timeline
Peripheral drying effects begin — subtle dry mouth and mild sedation emerge. No significant cognitive or perceptual changes yet.
Full antimuscarinic profile established — significant dry mouth, sedation, anterograde amnesia, and blurred vision from cycloplegia. Cognitive impairment is measurable; nausea suppression is maximal.
Gradual return of salivation and clearing of sedation. Cognitive effects (amnesia, attentional impairment) may persist beyond subjective resolution of other effects.
⚠ Avoid driving or operating machinery for at least 6 hours after oral scopolamine due to persistent sedation, blurred vision, and cognitive impairment.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- Low
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- atropine · diphenhydramine · other anticholinergic agents
Toxicity
Acute toxicity
Scopolamine toxicity presents as the classic anticholinergic pattern: no sweating, dilated pupils, flushed skin, elevated temperature, rapid heart rate, and delirium.[4] Toxic delirium has been reported from standard patches in children[25] and adults — confirming that the therapeutic window is narrow.
No reliable human lethal dose has been established. Clinical estimates suggest 10 mg/day may be lethal in children, while adults have survived doses exceeding 100 mg/day.[4]safety citation needed
Organ-specific effects
Rapid heart rate is the primary cardiovascular effect; cardiovascular collapse is not typical from scopolamine alone but may occur from excessive physostigmine treatment.[26] Pupil dilation can trigger acute angle-closure glaucoma in anatomically predisposed individuals.[4] Blocked sweat glands impair heat dissipation — overheating is a serious risk in warm environments or during physical exertion.[4]
Urinary retention is common, particularly in men with enlarged prostates.[4] Scopolamine crosses the placenta and is present in breast milk; caution is advised during pregnancy and lactation.[1]
Long-term risk
Cumulative anticholinergic medication use is associated with increased cognitive decline and dementia risk in older adults.[5] Perioperative scopolamine use has been specifically linked to increased dementia incidence in older surgical patients.[24] The significance for occasional use — such as transdermal patches for travel — has not been quantified.
Psychological risks
The primary psychological risk is anticholinergic delirium — an acute confused state with disorientation, agitation, vivid hallucinations, paranoia, and loss of reality-testing.[4] This can occur at therapeutic doses in children, the elderly, and those with pre-existing cognitive impairment.[25][27]
Anterograde amnesia — the inability to form new memories — is a hallmark effect at all doses above threshold. Victims of involuntary intoxication experience severe memory loss combined with enhanced suggestibility, enabling compliance with criminal directives without subsequent recall.[2] The hallucinations are realistic and mundane — phantom cigarettes, absent people, ordinary objects — not geometric or abstract.
Tolerance and dependence
No controlled human studies on tolerance have been published. Transdermal data show no reduction in efficacy during sustained use.[9] Dependence liability at clinical doses is negligible; scopolamine is not a controlled substance in any major jurisdiction.[28]
Abrupt removal of a transdermal patch after sustained use can trigger cholinergic rebound effect: nausea, vomiting, cramping, sweating, and headache.[29] One documented case showed progressively worsening rebound with each use-withdrawal cycle, suggesting the rebound response can intensify over repeated exposure.[30]
Drug Interactions
The most significant interaction is additive anticholinergic burden. Combining scopolamine with other anticholinergic drugs — tricyclic antidepressants, first-generation antipsychotics, antihistamines, bladder medications, anti-Parkinson drugs — compounds muscarinic blockade and sharply raises the risk of delirium, bowel obstruction, and urinary retention.[4][27]
CNS depressants — opioids, benzodiazepines, alcohol, sedating antihistamines — add to scopolamine's sedation and can suppress breathing.[4] Opioids also carry intrinsic anticholinergic properties, compounding constipation and urinary retention.[27]
Drugs that raise acetylcholine — dementia medications such as donepezil and rivastigmine — counteract scopolamine directly.[18] This is the pharmacological basis for physostigmine as an antidote. Certain liver-enzyme inhibitors increase scopolamine exposure; grapefruit juice raises blood levels to approximately 142% of normal.[1]safety citation needed
Contraindications
13 knownAbsolute:
- Angle-closure glaucoma — scopolamine's pupil-dilating effect can trigger an acute glaucoma crisis[4]
- Allergy to belladonna alkaloids — cross-reactivity among tropane alkaloids[4]
Relative:
- Myasthenia gravis — unpredictable effects on neuromuscular transmission[4]
- Severe preeclampsia — risk of precipitating eclampsia[4]
- Enlarged prostate or urinary retention — risk of acute urinary retention[4]
- Significant liver or kidney impairment — reduced clearance increases toxicity risk[4]
- Elderly with cognitive impairment — high risk of anticholinergic delirium[27]
- Children — increased sensitivity to CNS effects; toxic psychosis reported from standard patches[25]
Harm Reduction[edit]
Forms & Identification
Pharmaceutical scopolamine comes in well-characterized forms — patches, tablets, injections — where dose and identity are known. No field test can determine the alkaloid content of Datura seeds, Brugmansia flowers, or any plant-derived tea or decoction.
Dose estimation from plant material is impossible. Alkaloid content varies by orders of magnitude between individual plants and between parts of the same plant. A "usual amount" of seeds has no pharmacological meaning.
Guidelines
- Never attempt to dose plant-derived scopolamine. Alkaloid content is inherently unpredictable. No prior experience establishes a safe dose.
- Pharmaceutical formulations only. Follow prescribing instructions exactly. Do not apply multiple patches simultaneously.
- Wash hands after handling patches. Residual scopolamine on fingers can transfer to eyes, causing prolonged pupil dilation.
- Do not cut patches. Cutting destroys the controlled-release mechanism and may deliver an unpredictable dose.
- Have a sitter present for any non-clinical exposure. The sitter must understand the person may become agitated, confused, and physically active while completely disoriented.
- Stay cool and hydrated. Scopolamine blocks sweating — overheating is a real danger in warm environments.
Set & Setting
Scopolamine delirium cannot be guided or navigated. Individuals in anticholinergic delirium lose the ability to distinguish hallucination from reality, cannot communicate reliably, and will not remember the experience. Traditional harm reduction principles do not apply — the capacity for intentional experience is abolished.
If exposure to anticholinergic plant material occurs despite the risks, a sober, informed sitter in a physically safe enclosed space is not optional. Remove access to vehicles, sharp objects, heights, and exits to public spaces.
Aftercare & integration. Recovery from anticholinergic delirium may take 24–72 hours. During this time, short-term memory and attention may remain impaired. Stay in a safe, familiar environment and avoid driving or operating machinery until cognitive clarity returns.
Rehydration and restoration of normal body temperature are the immediate priorities. Resume normal eating when gut motility returns — constipation and reduced appetite are common residual effects. Individuals who experienced involuntary scopolamine intoxication may face significant psychological distress from the combination of amnesia and awareness of having complied with criminal directives; professional psychological support is strongly recommended.[2]
Recovery & Support
Scopolamine does not produce the compulsive redosing patterns associated with stimulants or opioids, and dependence at clinical doses is negligible. Abrupt removal of a transdermal patch after sustained use can trigger nausea, sweating, cramping, and headache.[29]
If withdrawal symptoms occur, gradual tapering under medical supervision is preferable to abrupt removal. Individuals who have experienced repeated or severe anticholinergic crises should consider medical evaluation including cognitive screening, given the association between cumulative anticholinergic exposure and long-term cognitive decline.[5]
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
The line from uncomfortable effects to a medical emergency is crossed when any of the following appear: body temperature rising with dry, flushed skin and no sweating; heart rate above 120 bpm at rest; seizure activity; inability to urinate; severe agitation with self-harm risk; or complete loss of orientation to person, place, and time.
Immediate steps:
- Call emergency services immediately if temperature is elevated, seizures occur, or the person is unresponsive.
- Move to a cool environment. Remove excess clothing. Apply cool water to skin if overheating.
- Do not restrain unless there is immediate danger of self-harm or harm to others — restraint increases agitation and heat generation.
- Do not induce vomiting.
- Keep the environment calm and low-stimulation. Speak in short, simple sentences.
What to tell the dispatcher: Name the substance (scopolamine or the plant involved), estimated amount and time of exposure, and current symptoms — especially temperature, heart rate, and mental status. Good Samaritan laws in many jurisdictions protect people who call for help during drug emergencies.
Reversal agent: Physostigmine is the specific antidote for anticholinergic delirium, given intravenously at 0.5–1 mg by medical professionals only. Excessive dosing risks cholinergic toxicity; seizures occur in up to 2.5% of treated cases.[26] Rivastigmine has been proposed as an alternative when physostigmine is unavailable.[31] Hospital treatment is the only route to these interventions.
Legal Status[edit]
Scopolamine is not a controlled substance in any major jurisdiction — its regulation is handled through medicines licensing rather than narcotics law, reflecting its status as an approved medication that also produces profound psychoactive effects.[3]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not DEA-scheduled; prescription required for pharmaceutical formulations | Pure compound is federally uncontrolled. Transderm Scōp patch and injectable scopolamine hydrobromide require prescription. The Federal Analogue Act is theoretically applicable if intended for human consumption, though no known prosecutions have occurred[28] |
| United Kingdom | Not controlled under Misuse of Drugs Act 1971; POM / OTC depending on formulation | Scopoderm TTS (patch) is prescription-only. Lower-dose hyoscine hydrobromide tablets (Kwells, Joy-Rides) are available over the counter for motion sicknesscitation needed |
| European Union | Medicinal product; not a narcotics-controlled substance | Regulated under national medicines legislation in member states; prescription required in most jurisdictions |
| Canada | Prescription medication; not a controlled substance | Available by prescription as part of combination preparations and transdermal formulations |
| Australia | Scheduled under SUSMP; pharmacy medicine (butylbromide) / prescription (hydrobromide) | Hyoscine butylbromide (Buscopan) available OTC with pharmacist guidance. Transdermal scopolamine hydrobromide requires prescription |
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- Low
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- atropine · diphenhydramine · other anticholinergic agents
Toxicity
Acute toxicity
Scopolamine toxicity presents as the classic anticholinergic toxidrome, summarized clinically as: "dry as a bone (no sweating), blind as a bat (dilated pupils), red as a beet (flushed skin), hot as a hare (elevated temperature), mad as a hatter (delirium)".[4]
No reliable human lethal dose has been established. Clinical estimates suggest 10 mg/day may be lethal in children, while adult survival has been documented at doses exceeding 100 mg/day.[4]safety citation needed The therapeutic window is narrow: toxic psychosis has been reported from standard transdermal patches in both children[26] and adults.
Organ-specific effects
Heart: Rapid heart rate from muscarinic blockade at the heart's pacemaker node is the primary cardiovascular effect. Cardiovascular collapse is not typical of scopolamine toxicity alone but may occur with physostigmine overdosing during treatment.[27]
Eyes: pupil dilation can trigger acute angle-closure glaucoma in anatomically predisposed individuals.[4]
Urinary: Urinary retention, particularly in men with enlarged prostate.[4]
Temperature: Blocked sweat glands impair heat dissipation; overheating is a serious risk in hot environments or during physical exertion.[4]
Pregnancy: Scopolamine crosses the placenta and enters breast milk; caution is advised in pregnancy and lactation.[1]
Long-term risk
Cumulative anticholinergic medication exposure is associated with increased risk of cognitive decline and dementia in older adults.[5] Perioperative anticholinergic use, including scopolamine, has been specifically linked to increased dementia incidence among older surgical patients.[25] The clinical significance for occasional use (e.g., transdermal patches for travel) has not been quantified.
Psychological risks
The primary psychological risk is anticholinergic delirium — an acute confusional state with disorientation, agitation, vivid hallucinations, paranoia, and impaired reality testing.[4] This can occur at therapeutic doses in vulnerable populations: children, elderly individuals, and those with pre-existing cognitive impairment.[26][28]
Anterograde amnesia is a hallmark effect at all dose ranges above threshold. Victims of involuntary scopolamine intoxication experience severe memory loss for the intoxication period combined with enhanced suggestibility, enabling compliance with criminal directives without subsequent recall.[2] Delusions of sobriety compound the danger: affected individuals cannot recognize their own impairment.[2]
The hallucinatory state is qualitatively distinct from serotonergic psychedelic hallucinations. It features realistic, often mundane visual content — phantom cigarettes, conversations with absent people, shadow figures — rather than geometric or abstract imagery.
Tolerance and dependence
No controlled human studies on tolerance to scopolamine have been published. Transdermal data show no pharmacokinetic tolerance — plasma levels and clinical efficacy remain consistent during sustained use.[10]
Cholinergic rebound withdrawal occurs upon abrupt discontinuation: nausea, vomiting, abdominal cramping, excessive sweating, headache, and muscle spasms.[29] A documented case following standard 7-day transdermal use showed progressive worsening of withdrawal symptoms with each successive use/withdrawal cycle, suggesting sensitization of the rebound effect response.[30]
Dependence liability at clinical doses is negligible. Scopolamine is not a scheduled controlled substance in any major jurisdiction.[31]
Drug Interactions
The most significant interaction involves additive anticholinergic burden. Combining scopolamine with other anticholinergic agents — tricyclic antidepressants, first-generation antipsychotics, antihistamines (diphenhydramine, hydroxyzine), bladder medications (oxybutynin, tolterodine), and anti-Parkinson drugs (trihexyphenidyl, benztropine) — produces cumulative muscarinic blockade with increased risk of delirium, bowel obstruction, and urinary retention.[4][28]
CNS depressants (opioids, benzodiazepines, alcohol, sedating antihistamines) produce additive sedation and respiratory depression when combined with scopolamine.[4] Opioids deserve specific mention: they carry intrinsic anticholinergic properties, so the combination compounds both sedation and peripheral effects (constipation, urinary retention).[28]
Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are pharmacologically antagonistic — they increase the acetylcholine that scopolamine blocks.[18] This is the pharmacological basis for physostigmine as an antidote.
CYP3A inhibitors increase scopolamine exposure. Grapefruit juice increases exposure to approximately 142% of normal.[1] Other CYP3A inhibitors (ketoconazole, erythromycin, ritonavir) would be expected to produce similar effects.safety citation needed
Contraindications
13 knownAbsolute:
- Angle-closure glaucoma — scopolamine's pupil-dilating effect can trigger an acute glaucoma crisis[4]
- Allergy to belladonna alkaloids — cross-reactivity among tropane alkaloids[4]
Relative:
- Myasthenia gravis — unpredictable effects on neuromuscular transmission[4]
- Severe preeclampsia — risk of precipitating eclampsia[4]
- Enlarged prostate or urinary retention — risk of acute urinary retention[4]
- Significant liver or kidney impairment — reduced clearance increases toxicity risk[4]
- Elderly with cognitive impairment — high risk of anticholinergic delirium[28]
- Children — increased sensitivity to CNS effects; toxic psychosis reported from standard patches[26]
Harm Reduction[edit]
Forms & Identification
Pharmaceutical scopolamine comes in well-characterized forms — transdermal patches, tablets, and injectable solutions — where dose and identity are known. The danger lies in plant-derived exposure, where no field test can determine the alkaloid content of a given seed, leaf, or tea. Datura seeds from the same pod can vary substantially in scopolamine concentration, and no identification method can distinguish scopolamine-dominant from atropine-dominant plant material.
For anyone handling Solanaceae plant material, the critical principle is that dose estimation is impossible. A "usual amount" of seeds or tea has no pharmacological meaning when alkaloid content varies by orders of magnitude between preparations.
Guidelines
- Never attempt to dose plant-derived scopolamine. Alkaloid content is inherently unpredictable. No amount of prior experience establishes a "safe dose."
- Pharmaceutical formulations only. If clinical scopolamine is being used for motion sickness or other indications, follow prescribing instructions exactly. Do not apply multiple patches simultaneously.
- Wash hands after handling patches. Residual scopolamine on fingers can transfer to eyes, causing prolonged pupil dilation.
- Do not cut patches. Transdermal patches are designed for controlled release from the intact system; cutting destroys the release mechanism and may deliver an unpredictable dose.
- Have a sitter present for any non-clinical exposure. The sitter must understand that the person may become agitated, confused, and physically active while completely disoriented.
- Stay hydrated and cool. Scopolamine impairs sweating — overheating is a real danger, especially in warm environments.
Set & Setting
Scopolamine delirium is not a psychedelic experience — it cannot be guided, directed, or navigated. Individuals in anticholinergic delirium lose the ability to distinguish hallucination from reality, cannot reliably communicate, and will not remember the experience afterward. Traditional "set and setting" principles do not apply in any meaningful way because the capacity for intentional experience is abolished.
If exposure to anticholinergic plant material occurs despite the risks, a sober informed sitter in a physically safe enclosed space is not optional — it is the single most important harm reduction measure. Remove access to vehicles, sharp objects, heights, bodies of water, and exits to public spaces.
Aftercare & integration. Recovery from anticholinergic delirium may take 24–72 hours depending on route and dose. During this period, cognitive function — especially short-term memory and attention — may remain impaired. Stay in a safe, familiar environment and avoid driving or operating machinery until cognitive clarity fully returns.
Rehydration and restoration of normal body temperature are the immediate physical priorities. Resume normal eating when gut motility returns — constipation and reduced appetite are common residual effects. For individuals who experienced involuntary scopolamine exposure in a criminal context, the combination of amnesia and awareness of having complied with directives during intoxication can produce significant psychological distress; professional psychological support is strongly recommended.[2]
Recovery & Support
Scopolamine does not produce the compulsive redosing patterns associated with stimulants or opioids, and dependence at clinical doses is negligible. However, cholinergic rebound effect withdrawal — nausea, sweating, cramping, headache — can follow abrupt discontinuation of transdermal patches after sustained use.[29]
If withdrawal symptoms occur after transdermal use, gradual tapering under medical supervision is preferable to abrupt removal. For individuals who have experienced repeated or severe anticholinergic crises, medical evaluation including cognitive screening is advisable given the association between cumulative anticholinergic exposure and long-term cognitive decline.[5]
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
The line between uncomfortable anticholinergic effects and a medical emergency is crossed when any of the following appear: body temperature rising with dry, flushed skin and no sweating; heart rate exceeding 120 bpm at rest; seizure activity; inability to urinate despite a full bladder; severe agitation with risk of self-harm; or complete loss of orientation to person, place, and time.
Immediate steps:
- Call emergency services immediately if temperature is elevated, seizures occur, or the person is unresponsive.
- Move the person to a cool environment. Remove excess clothing. Apply cool water to skin if overheating.
- Do not restrain unless there is immediate danger of self-harm or harm to others — restraint increases agitation and heat generation.
- Do not induce vomiting.
- Keep the person in a calm, low-stimulation environment. Speak in short, simple sentences.
What to tell the dispatcher: Name the substance (scopolamine or the plant involved), estimated amount and time of exposure, and current symptoms — especially temperature, heart rate, and mental status. Good Samaritan laws in many jurisdictions protect people who call for help during drug emergencies.
Reversal agent: Physostigmine is the specific antidote for anticholinergic delirium, administered intravenously at 0.5–1 mg by medical professionals only. Excessive dosing carries risk of cholinergic toxicity; seizures occur in up to 2.5% of treated cases.[27] Rivastigmine has been proposed as an alternative when physostigmine is unavailable.[32] Hospital treatment is the only route to these interventions.
Legal Status[edit]
Scopolamine occupies an unusual regulatory position among psychoactive compounds: despite producing profound psychoactive effects including delirium, hallucinations, and amnesia, it is not classified as a controlled substance in any major jurisdiction. Its regulation is determined by medicines scheduling (prescription requirements) rather than narcotics control legislation. Scopolamine appears on the WHO Model List of Essential Medicines[3] and is not listed in the UN Convention on Psychotropic Substances (1971).
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not DEA-scheduled; prescription required for pharmaceutical formulations | Pure compound is federally uncontrolled. Transderm Scōp patch and injectable scopolamine hydrobromide require prescription. The Federal Analogue Act is theoretically applicable if intended for human consumption, though no known prosecutions have occurred[31] |
| United Kingdom | Not controlled under Misuse of Drugs Act 1971; POM / OTC depending on formulation | Scopoderm TTS (patch) is prescription-only. Lower-dose hyoscine hydrobromide tablets (Kwells, Joy-Rides) are available over the counter for motion sicknesscitation needed |
| European Union | Medicinal product; not a narcotics-controlled substance | Regulated under national medicines legislation in member states; prescription required in most jurisdictions |
| Canada | Prescription medication; not a controlled substance | Available by prescription as part of combination preparations and transdermal formulations |
| Australia | Scheduled under SUSMP; pharmacy medicine (butylbromide) / prescription (hydrobromide) | Hyoscine butylbromide (Buscopan) available OTC with pharmacist guidance. Transdermal scopolamine hydrobromide requires prescription |
Frequently asked questions
What is Scopolamine?
Scopolamine is a naturally occurring tropane alkaloid and muscarinic acetylcholine receptor antagonist classified as a deliriant. First isolated in 1880, it is FDA-approved for motion sickness and postoperative nausea prophylaxis and is under investigation as a rapid-acting antidepressant.
How long does Scopolamine last?
Total duration by route of administration — Oral: 4 – 6 hours; Transdermal: 72 – 72 hours; Intravenous: 4 – 6 hours; Subcutaneous: 3 – 6 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Scopolamine?
Psychedex publishes a dosage table for Scopolamine on this page covering these routes of administration: oral, transdermal, intravenous, nasal_spray. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Scopolamine?
The highest-severity documented interactions for Scopolamine: Amphetamines (Dangerous), Antihistamines (Dangerous), Antipsychotics (Dangerous), Atypical antipsychotics (Dangerous), Buprenorphine, Kratom (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Scopolamine addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Scopolamine: tolerance builds none; cross-tolerance develops with atropine, diphenhydramine, other anticholinergic agents. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abcReichert S, Lin C, Ong W, Him CC, Hameed S (2017) Million dollar ride: Crime committed during involuntary scopolamine intoxication — Canadian Family Physician PMID:28500194
- [3] ^abcdShim KH, Kang MJ, Sharma N, An SSA (2022) Beauty of the beast: anticholinergic tropane alkaloids in therapeutics — Natural Products and Bioprospecting doi:10.1007/s13659-022-00357-w
- [4]
- [5] ^abcdZiadeh H, Rhodes S, Sheyn D, Hijaz A (2024) Risk of dementia associated with the use of anticholinergic medications: a review of recent literature — Current Opinion in Urology doi:10.1097/mou.0000000000001211
- [6] ^abcChen JCC, Sumner RL, Naga VK, et al. (2022) A Randomized Controlled Trial of Intravenous Scopolamine Versus Active-Placebo Glycopyrrolate in Patients With Major Depressive Disorder — Journal of Clinical Psychiatry doi:10.4088/jcp.21m14310
references
- [1]
- [2] ^abcdReichert S, Lin C, Ong W, Him CC, Hameed S (2017) Million dollar ride: Crime committed during involuntary scopolamine intoxication — Canadian Family Physician PMID:28500194
- [3] ^abcdShim KH, Kang MJ, Sharma N, An SSA (2022) Beauty of the beast: anticholinergic tropane alkaloids in therapeutics — Natural Products and Bioprospecting doi:10.1007/s13659-022-00357-w
- [4]
- [5] ^abcdZiadeh H, Rhodes S, Sheyn D, Hijaz A (2024) Risk of dementia associated with the use of anticholinergic medications: a review of recent literature — Current Opinion in Urology doi:10.1097/mou.0000000000001211
- [6] ^abcChen JCC, Sumner RL, Naga VK, et al. (2022) A Randomized Controlled Trial of Intravenous Scopolamine Versus Active-Placebo Glycopyrrolate in Patients With Major Depressive Disorder — Journal of Clinical Psychiatry doi:10.4088/jcp.21m14310